Last 40,550 KRW
Change Today -550.00 / -1.34%
Volume 39.5K
003850 On Other Exchanges
Korea SE
As of 1:10 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

boryung pharmaceutical co (003850) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/9/15 - 46,200
52 Week Low
03/27/14 - 33,992
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BORYUNG PHARMACEUTICAL CO (003850)

Related News

No related news articles were found.

boryung pharmaceutical co (003850) Related Businessweek News

No Related Businessweek News Found

boryung pharmaceutical co (003850) Details

Boryung Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers various active pharmaceutical ingredients, including doxorubicin hydrochloride, tamsulosin hydrochloride, epirubicin hydrochloride, glimepiride, captopril, alibendole, alacepril, torsemide, nitrendipine, fluconazole, and ondansetron hydrochloride. It also manufactures and licenses various finished products in the areas of antibiotics, dermatology, cardiovascular, antineoplastics and antiemetics, urology, gastrointestinal, amino acids injections, dialysis, antidiabetes, CNS, vaccines, respiratory, anti-histamines, and ophthalmics, as well as antipyretic, analgesics, anti-inflammatory, and other areas. The company was formerly known as Boryung Drugs Co., Ltd. and changed its name to Boryung Pharmaceutical Co., Ltd. in February 1966. Boryung Pharmaceutical Co., Ltd. was founded in 1963 and is headquartered in Seoul, South Korea.

Founded in 1963

boryung pharmaceutical co (003850) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

boryung pharmaceutical co (003850) Key Developments

Boryung Pharmaceutical Co., Ltd. Enters into Contract with Harbin Gloria Pharmaceuticals Co., Ltd

Boryung Pharmaceutical Co., Ltd. has announced a licensing deal with China's Harbin Gloria Pharmaceuticals in relation to the former's hypertension treatment Kanarb (fimasartan). The deal grants Gloria marketing rights to the drug in China, which will be manufactured and supplied by Boryung. As reported by the Ministry of Health and Welfare (MHW), the entire contract is worth KRW 80 billion (USD 74.8 million), including a USD 5.5-million upfront payment.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
003850:KS 40,550.00 KRW -550.00

003850 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,417 GBp -6.50
View Industry Companies

Industry Analysis


Industry Average

Valuation 003850 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BORYUNG PHARMACEUTICAL CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at